Akari Therapeutics
AKTX
11 hedge funds and large institutions have $394K invested in Akari Therapeutics in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
38% more funds holding
Funds holding: 8 → 11 (+3)
0% less ownership
Funds ownership: 0% → 0% (-0%)
27% less capital invested
Capital invested by funds: $536K → $394K (-$142K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$275K |
| 2 |
CCG
Catalina Capital Group
Torrance,
California
|
+$24.7K |
| 3 |
ACM
Accent Capital Management
Centerville,
Ohio
|
+$18.8K |
| 4 |
Renaissance Technologies
New York
|
+$10.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$376 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$99.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAI
1
Palo Alto Investors
Palo Alto,
California
| $178K | +$275K | +3,651 | New |
|
|
OFW
2
Omnia Family Wealth
Aventura,
Florida
| $107K | – | – | – |
|
3
Cerity Partners
New York
| $28.8K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $28.6K | +$10.2K | +135 | +30% |
|
|
CAM
5
Cresset Asset Management
Chicago,
Illinois
| $22.5K | – | – | – |
|
|
CCG
6
Catalina Capital Group
Torrance,
California
| $16K | +$24.7K | +328 | New |
|
|
ACM
7
Accent Capital Management
Centerville,
Ohio
| $12.2K | +$18.8K | +250 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| $237 | +$376 | +5 | New |
|
9
Bank of America
Charlotte,
North Carolina
| $183 | – | – | – |
|
10
Osaic Holdings
Scottsdale,
Arizona
| $122 | – | – | – |
|
|
TC
11
Truvestments Capital
Sarasota,
Florida
| $61 | – | – | – |
|
12
Morgan Stanley
New York
| $7 | – | – | – |
|
|
CPG
13
Cornerstone Planning Group
Fairfield,
New Jersey
| $6 | – | – | – |
|
|
SS
14
SBI Securities
Tokyo,
Japan
| $6 | – | – | – |
|
|
15
Citadel Advisors
Miami,
Florida
| – | -$99.1K | -832 | Closed |
|
AKTX Hedge Fund Activity: Q4 2024 in Review
11 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q4 2024, worth a combined $394K — down 27% from $536K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new AKTX positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Palo Alto Investors, opening a new position worth an estimated $275K. The largest seller was Citadel Advisors, exiting entirely with an estimated $99.1K sold.
- 11 institutional investors held Akari Therapeutics (AKTX) as of Q4 2024, up from 8 in Q3 2024.
- Funds reported $394K of Akari Therapeutics stock for Q4 2024, down 27% quarter-over-quarter.
- 4 funds opened new Akari Therapeutics positions in Q4 2024 and 1 closed out, a net change of +3 holders.
- The largest Akari Therapeutics buyer in Q4 2024 was Palo Alto Investors, an estimated $275K added.
- The largest Akari Therapeutics seller in Q4 2024 was Citadel Advisors, an estimated $99.1K sold.
Based on aggregated 13F filings for Q4 2024.